Independent urology practices head into 2027 facing a conversion factor cut, prior authorization hurdles, and Part B drug price negotiation, according to Gary Kirsh, MD.
|Videos|December 9, 2022
Dr. Antonarakis on available prostate cancer treatments driven by genetic testing
Author(s)Urology Times staff
Advertisement
Emmanuel S. Antonarakis, MD, discusses FDA-approved treatments currently available for prostate cancer that are selected based on genetic testing of patients. Antonarakis is associate director for Translational Research at the University of Minnesota Medical School Masonic Cancer Center, as well as the Clark Endowed Professor of Medicine and director of Genitourinary Oncology in the Department of Medicine’s Division of Hematology, Oncology, and Transplantation
Advertisement
Related to this article
Updated CAPItello-281 data support capivasertib plus abiraterone in PTEN-deficient mHSPC, according to Daniel J. George, MD.
Benjamin Garmezy, MD, discusses personalizing mHSPC treatment intensification based on disease burden, molecular biomarkers, and patient-specific factors.
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
Biomarkers including HRR mutations, PTEN loss, and PSMA expression can guide triplet selection in mHSPC, according to Benjamin Garmezy, MD.
William Huang, MD, discusses histotripsy for renal tumors, the #HOPE4KIDNEY trial, and the technology’s potential to preserve kidney function.
Systemic therapy now anchors MIBC care and expands bladder preservation options, according to Joshua J. Meeks, MD, PhD.
BCG optimization should precede checkpoint inhibitor intensification in BCG-naive high-risk NMIBC, according to Tom Jayram, MD.
Advertisement
Advertisement
Trending on Urology Times
1
Treating MIBC as a systemic disease reshapes bladder preservation
2
Patient priorities guide treatment choice in BCG-unresponsive NMIBC
3
DASL-HiCaP Interim Results in Very High-Risk Localized Prostate Cancer
4
Talazoparib triplet joins treatment options for HRR-mutated mHSPC
5